3 unchanged sentences
10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
−Removed: On May 13, 2026, the Company and Christopher Downs,
−Removed: the Company’s Senior Vice President – Finance, entered into a Separation and Severance Agreement, which memorializes the terms
−Removed: Down’s separation from service with the Company.
−Removed: Pursuant to the agreement, subject to Mr.
−Removed: Down’s timely execution,
−Removed: non-revocation, and compliance with the agreement’s terms, the Company will provide severance benefits, equal to six months of Mr.
−Removed: Down’s current annualized base salary, paid in accordance with the Company’s regular payroll cycle.
+Added: On August 11, 2026, Michal Fisher was nominated
+Added: and appointed to serve as a member of our Compensation Committee.
+Added: Fisher was appointed to our Board of Directors on May 4, 2026.
+Added: On August 12, 2026, the Company entered into
+Added: indemnification agreements with each of its directors and executive officers.
INDEX TO EXHIBITS
1 unchanged sentence
and A.G.P./Alliance Global Partners (filed as Exhibit 1.1 to the Company’s Form 8-K filed May 4, 2026)
−Removed: Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Company’s
−Removed: Form 8-K filed May 4, 2026)
−Removed: Employment Agreement between Steve O’Loughlin and CNS Pharmaceuticals, Inc.
−Removed: dated February 10, 2026 (filed as Exhibit 10.1 to the Company’s Form 8-K filed February 17, 2026)
−Removed: Employment Agreement between Christopher Downs and CNS Pharmaceuticals, Inc.
−Removed: dated February 13, 2026 (filed as Exhibit 10.2 to the Company’s Form 8-K filed February 17, 2026)
−Removed: Employment Agreement between Lynne Kelley and CNS Pharmaceuticals, Inc.
−Removed: dated February 26, 2026 (filed as Exhibit 10.1 to the Company’s Form 8-K filed March 2, 2026)
−Removed: Separation and Severance Agreement between Sandra Silberman and CNS Pharmaceuticals, Inc.
−Removed: dated February 27, 2026 (filed as Exhibit 10.2 to the Company’s Form 8-K filed March 2, 2026)
−Removed: Employment Agreement between Eric Faulkner and CNS Pharmaceuticals, Inc.
−Removed: dated February 10, 2026 (filed as Exhibit 10.19 to the Company’s Form 10-K filed March 31, 2026)
+Added: Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Company’s Form 8-K filed May 4, 2026)
Form of Securities Purchase Agreement dated May 4, 2026 (filed as Exhibit 10.1 to the Company’s Form 8-K filed May 4, 2026)
Form of Registration Rights Agreement dated May 4, 2026 (filed as Exhibit 10.2 to the Company’s Form 8-K filed May 4, 2026)
+Added: Separation and Severance Agreement dated May 13, 2026 between Christopher Downs and CNS Pharmaceuticals, Inc.
+Added: Form of Indemnification Agreement
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
21 unchanged sentences
Chief Executive Officer, President
+Added: August 12, 2026
(Principal Executive Officer)
1 unchanged sentence
Chief Financial Officer
+Added: August 12, 2026
Steve O’Loughlin
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.